LAUSR

Thirty years ago, the International Prognostic Index (IPI) for aggressive lymphomas was published by Shipp and colleagues in the New England Journal of Medicine.1 Although the pathologic classification schema for lymphoma has evolved dramatically with the introduction of immunohistochemical and molecular testing, the IPI remains relevant today. At the time of publication, the paper was groundbreaking in many ways. The work was an international collaboration (16 institutions and co-operative groups across the US, Canada and Europe) with a very large data set used for discovery and validation. The five risk factors of age (> 60 years), stage (3/4), more than one extranodal site, performance status (> or = to 2), and elevated lactate dehydrogenase, are simple and accessible across all regions, including resource-poor settings. The IPI has held the test of time. It is used in most prospective, randomized trials to stratify risk and ensure balance between groups. In nearly all retrospective analyses, the IPI is an independent prognostic factor for progression-free and overall survival on multivariate analysis. The IPI also sheds light on why the outcomes of clinical trials are uniformly more favorable than in the “real world”. Patients with high-risk disease are under-represented in clinical trials. This reflects, in part, the difficulty of enrolling patients on a study who have high-risk disease and may be hospitalized and/or in urgent need of therapy. In addition, it facilitates the investigation of the independent impact of other prognostic biomarkers through adjusted analyses. The IPI inspired other clinical prognostic scales across Ann S. LaCasce